Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2016

View Archived Issues

Trial supports the use of sodium channel blocker phenytoin in acute optic neuritis

Pivotal phase III clinical trial of intravenous meloxicam begins at Recro Pharma

FDA accepts BLA for bezlotoxumab

Supinoxin demonstrates preclinical efficacy to treat renal cancer

Replikins selects peptide Zika virus vaccine for preclinical efficacy studies

Sumitomo Dainippon Pharma updates progress of third quarter of fiscal 2015

Blend Therapeutics secures Series C financing and changes name

Urine-exosome signature validated in prostate cancer patients

Roche Diagnostics and Lilly to develop Alzheimer's diagnostic

Stemedica completes enrollment in phase I/IIa study in stroke

MSI Methylation Sciences reports results from phase II trial of MSI-195 in MDD

Alpharmagen discloses nicotinic acetylcholine alpha7 modulators

University of Texas System patents mitochondrial GLS inhibitors

Serendex starts phase II trial of inhaled molgramostim in ARDS

BIND Therapeutics gives update on BIND-014 trials

ImmunoCellular Therapeutics enters research agreement with the University of Maryland

Aprecia Pharmaceuticals obtains financing to advance 3D-printed drug pipeline

Clovis begins phase Ib/II study of atezolizumab and rociletinib

Cyramza approved in Europe for NSCLC and colorectal cancer

First patient dosed in Zimura phase II/III trial

Breakthrough therapy designation for venetoclax for AML

Incyte to stop substudy within ruxolitinib phase II colorectal cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...